Tea Gunde, Ph.D.Vice President, Discovery at Numab Therapeutics AG
Tea Gunde is Head of Discovery at Numab Therapeutics, a Swiss biotech company developing multiple immuno-oncology programs utilizing the versatile, multi-specific MATCH platform. Prior to joining Numab, Tea headed the pharmacokinetics & pharmacodynamics unit at ESBATech. She specialized in the discovery and preclinical development of therapeutic (bi-specific and multi-specific) antibodies for cancer immunotherapy. Tea led preclinical discovery and development projects in the field of ophthalmology and immuno-oncology and was instrumental in the discovery and the pre-clinical development of BEOVU®. In addition, she contributed to preclinical development of NM21-1480, an anti-PD-L1x4-1BBxSA scMATCH3 currently in active clinical development. Tea holds an MSc in Molecular Biology and Immunology from the University of Zurich, and a PhD in Molecular Biology from the University of Zurich.